Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A2269_Citrus_limon_LC/MS_Dr.Heba_SH._Mohammed

ABSTRACT: LC/MS of Citrus limon plant sample Dr. Heba Sh. Mohammed_2022_A2269

INSTRUMENT(S): Xevo TQD

ORGANISM(S): Citrus Limon (ncbitaxon:2708) Synergistes (ncbitaxon:2753)

SUBMITTER: Prof. Dr. Magdy Mostafa Desoky Mohammed

PROVIDER: MSV000090407 | MassIVE |

REPOSITORIES: MassIVE

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

E-PROT-106

Project description:Global proteome analysis of paired colorectal cancer sample using LC-MS/MS

2023-06-22 | E-PROT-106 | ExpressionAtlas

RNA-seq using human SH-SY5Y neuroblastoma cells used for SILAC experiment

Project description:To measure translational efficiency in FMRP depletion, we purified RNAs from either wild-type or FMR1-knockout (FMR1-KO) SH-SY5Y cells generated for SILAC coupled to LC-MS/MS analysis and performed RNA-seq to quantitate mRNA abundance to normalize their protein abundance.

2022-10-30 | GSE197221 | GEO

Proteomics_LC-MS_MS

Project description:Proteomics LC-MS MS dataset

| EGAD00010001006 | EGA

Mus musculus

Project description:Metabolomics LC-MS dataset

| PRJNA811808 | ENA

E-PROT-40

Project description:Human colon biopsies (healthy and Ulcerative Colitis) LC-MS/MS

2022-01-07 | E-PROT-40 | ExpressionAtlas

Anti-tumor activity and acquired resistance mechanism of Dovitinib (TKI258) in RET rearranged lung adenocarcinoma

Project description:RET rearrangement is a newly identified oncogenic mutation in lung adenocarcinoma (LADC). Activity of dovitinib (TKI258), a potent inhibitor of FGFR, VEGFR, and PDGFR, in RET-rearranged LADC has not been reported. The aims of the study are to explore anti-tumor effects and mechanisms of acquired resistance of dovitinib in RET-rearranged LADC. Using structural modeling and in vitro analysis, we demonstrated that dovitinib induced cell cycle arrest at G0/G1 phase and apoptosis by selective inhibition of RET kinase activity and ERK1/2 signaling in RET-rearranged LC-2/ad cells. Strong anti-tumor effect of dovitinib was observed in LC-2/ad tumor xenograft model. To identify the acquired resistance mechanisms to dovitinib, LC-2/ad cells were exposed to increasing concentrations of dovitinib to generate LC-2/ad DR cells. Gene set enrichment analysis of gene expression and receptor tyrosine kinase assay revealed that Src, a central gene in focal adhesion , was activated in LC-2/ad DR cells. Saracatinib, a src kinase inhibitor, suppressed ERK1/2 phosphorylation and growth of LC-2/ad DR cells. Taken together, these findings suggest that dovitinib can be a potential therapeutic option for RET-rearranged LADC, in which acquired resistance to dovitinib can be overcome by targeting Src. To identify potential mechanisms of acquired resistance to dovitinib, we established LC-2/ad DR cells with acquired resistance to dovitinib by exposing LC-2/ad cells to increasing doses of dovitinib. LC-2/ad DR cells showed strong resistance to dovitinib (IC50> 3 μmol/L). Next, LC-2/ad and LC-2/ad DR cells were subjected to genome-wide gene expression profiling using cDNA microarray.

2015-09-01 | E-GEOD-69226 | biostudies-arrayexpress

E-PROT-89

Project description:Rat testis LC-MS/MS - Integrated proteomics and metabolomics analysis of rat testis

2022-01-18 | E-PROT-89 | ExpressionAtlas

E-PROT-9

Project description:Fractionation-dependent improvements in proteome resolution in the mouse hippocampus by IEF LC-MS/MS

2022-01-14 | E-PROT-9 | ExpressionAtlas

Identification of targets of the protein disulfide reductase thioredoxin

Project description:Identification of targets of the protein disulfide reductase thioredoxin using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) and thiol specific differential labeling with isotope-coded affinity tags (ICAT). Reduction of specific target disulfides is quantified by measuring ratios of cysteine residues labeled with the heavy (13C) and light (12C) ICAT reagents in peptides derived from tryptic digests of Trx-treated and non-treated samples. Keywords: protein, LC-MS/MS, ICAT

2008-11-20 | GSE11650 | GEO

Anti-tumor activity and acquired resistance mechanism of Dovitinib (TKI258) in RET rearranged lung adenocarcinoma

2015-09-01 | GSE69226 | GEO